Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · July 19, 2022

Risk of New-Onset Psoriasis Associated With TNF-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases

JAMA Dermatology

 

Additional Info

JAMA Dermatology
Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study
JAMA Dermatol 2022 Jun 29;[EPub Ahead of Print], D Thein, A Egeberg, L Skov, N Loft

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading